Publicacions en què col·labora amb José Luis Ferreiro (12)

2022

  1. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

    Circulation, Vol. 146, Núm. 16, pp. 1196-1206

  2. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper

    Thrombosis and Haemostasis, Vol. 122, Núm. 10, pp. 1625-1652

  3. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 24, Núm. 11, pp. 1844-1871

  4. Current trends on antithrombotic therapy

    REC: CardioClinics

2021

  1. Comments on the 2020 ESC/EACTS guidelines for the management of atrial fibrillation

    Revista Espanola de Cardiologia, Vol. 74, Núm. 5, pp. 378-383

  2. Impact of sex differences and network systems on the in-hospital mortality of patients with ST-segment elevation acute myocardial infarction

    Revista Espanola de Cardiologia, Vol. 74, Núm. 11, pp. 927-934

  3. Sex differences in the management of patients with acute coronary syndrome: A population-based ecological cross-sectional study in Spain

    REC: CardioClinics, Vol. 56, Núm. 3, pp. 168-178

2020

  1. Impact of antithrombotic treatment and geriatric syndromes in octogenarians with atrial fibrillation and ischaemic heart disease. Atrial Fibrillation and Ischemic Heart Disease in the Elderly

    Revista Espanola de Geriatria y Gerontologia, Vol. 55, Núm. 6, pp. 338-342

  2. Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology

    Revista Espanola de Cardiologia, Vol. 73, Núm. 9, pp. 749-757

2019

  1. High and low on-treatment platelet reactivity to P2Y 12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention

    Thrombosis Research, Vol. 175, pp. 95-101

2018

  1. Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU

    Revista Espanola de Cardiologia, Vol. 71, Núm. 7, pp. 553-564

2016

  1. Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold

    Platelets, Vol. 27, Núm. 8, pp. 777-783